Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its full-year revenue outlook.

The biopharmaceutical company reported quarterly earnings of $0.27 per share, significantly surpassing the analyst consensus estimate of $0.19. Revenue for the quarter reached $214.3 million, also beating expectations and representing a 56% increase compared to the same period last year.

Investor sentiment was further bolstered by management's decision to raise its 2026 net product revenue guidance for its ARCALYST drug to a range of $930 million to $945 million, up from the previous forecast of $900 million to $920 million. This increased guidance reflects strong confidence in continued sales growth driven by expanding adoption of the treatment for recurrent pericarditis.